Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Differentiation of CHIP, ICUS, CCUS, MDS, and VEXAS Syndrome

MyCancerHaven

R. Vij, S. Abedin

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

PV and Its Relationship to Acute Leukemia

16th International Congress on Myeloproliferative Neoplasms

J. Spivak

Defining Risk of Progression in CHIP/CCUS: A Pathologists' Perspecti…

16th International Congress on Myeloproliferative Neoplasms

R. Hasserjian

What to Do When Patch Testing is Negative?

American Contact Dermatitis Society (ACDS)

M. Montanez-Wiscovich

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

Current and Emerging Treatment Approaches for Patients With AML or M…

University of Miami Sylvester Comprehensive Cancer Center

S. Venugopal

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez